CD8A and neoplasm: This indicates that the combination of Niraparib and Ezetimibe inhibits tumor growth by increasing the infiltration of CD8+ T cells in the tumor tissue, and the increased expression of Granzyme B suggests an enhanced cytolytic effect of the combination therapy on CD8+ T cells.